Wells Fargo & Company Foghorn Therapeutics Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding FHTX
# of Institutions
80Shares Held
33.3MCall Options Held
8.7KPut Options Held
2.4K-
Flagship Pioneering Inc. Cambridge, MA12.7MShares$99.4 Million20.03% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$41.6 Million1.57% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.03MShares$23.7 Million0.52% of portfolio
-
Raymond James & Associates St Petersburg, FL2.3MShares$18 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.73MShares$13.6 Million0.0% of portfolio
About Foghorn Therapeutics Inc.
- Ticker FHTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,637,400
- Market Cap $326M
- Description
- Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...